CRISPR-SWITCH (silent mutations with intention to create heterozygotes): a strategy for monoallelic genome editing and generation of a Syt1-D365E mouse model of Baker–Gordon syndrome
Frontiers in Genome Editing · 10.07.2026 · 8
DOI: 10.3389/fgeed.2026.1833024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Genome Editing, online erschienen am 10.07.2026. Verfasst von Samantha Norris und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Missouri, Columbia, MO, United States. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Precise control of allelic outcomes remains a major limitation of CRISPR-Cas9 genome editing, particularly for genes in which biallelic modification is lethal or confounds disease modeling. Here, we present CRISPR-SWITCH (Silent mutations With Intention To Create Heterozygotes), a genome engineering strategy that enables deliberate monoallelic editing by exploiting allele-specific CRISPR targeting. CRISPR-SWITCH operates through the initial introduction of a synonymous nucleotide substitution that creates a unique guide RNA recognition site, allowing subsequent selective editing of the engineered allele while preserving the wildtype copy. We applied CRISPR-SWITCH to generate a mouse model of Baker-Gordon syndrome, a dominant-negative neurodevelopmental disorder caused by pathogenic variants in synaptotagmin-1 ( SYT1 ). Conventional CRISPR-Cas9 editing of the Syt1 locus produced complex allelic outcomes characterized by biallelic editing and mosaicism, preventing reliable generation of the defined heterozygous genotype required for disease modeling. In contrast, CRISPR-SWITCH enforced heterozygosity by first introducing a synonymous Y364Y mutation and then selectively targeting this allele to install the pathogenic D365E variant. This approach produced viable Syt1 -D365E mice with exclusive monoallelic genome editing, predictable preservation of a wildtype allele, and balanced (1:1) expression of mutant and wildtype transcripts. Together, these results demonstrate proof-of-principle that CRISPR-SWITCH can enforce heterozygosity at endogenous loci and enable the generation of viable mammalian models for dominant-negative and dosage-sensitive genetic disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Missouri, Columbia, MO, United States.
Zitieren
APA
Norris, S., Yeddula, S. G. R., Su, E., Vandeloecht, K., Saunders, S., Wang, Y., Boychuk, C., Arnold, W. D., Lorson, C., & Davis, D. J. (2026). CRISPR-SWITCH (silent mutations with intention to create heterozygotes): a strategy for monoallelic genome editing and generation of a Syt1-D365E mouse model of Baker–Gordon syndrome. Frontiers in Genome Editing, 8. https://doi.org/10.3389/fgeed.2026.1833024
Vancouver
Norris S, Yeddula SGR, Su E, Vandeloecht K, Saunders S, Wang Y, et al. CRISPR-SWITCH (silent mutations with intention to create heterozygotes): a strategy for monoallelic genome editing and generation of a Syt1-D365E mouse model of Baker–Gordon syndrome. Frontiers in Genome Editing. 2026;8. doi:10.3389/fgeed.2026.1833024
BibTeX
@article{Norris2026,
author = {Norris, Samantha and Yeddula, Sai Goutham Reddy and Su, Elaine and Vandeloecht, Klancey and Saunders, Sandy and Wang, Yoko and Boychuk, Carie and Arnold, W David and Lorson, Christian and Davis, Daniel J},
title = {CRISPR-SWITCH (silent mutations with intention to create heterozygotes): a strategy for monoallelic genome editing and generation of a Syt1-D365E mouse model of Baker–Gordon syndrome},
journal = {Frontiers in Genome Editing},
year = {2026},
volume = {8},
doi = {10.3389/fgeed.2026.1833024}
}
EUVIMED